Tags

Type your tag names separated by a space and hit enter

Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.

Abstract

Little is known about biological predictors of treatment response in panic disorder. Our previous studies show that the brain-derived neurotrophic factor (BDNF) may play a role in the pathophysiology of major depressive disorders and eating disorders. Assuming that BDNF may be implicated in the putative common etiologies of depression and anxiety, the authors examined serum BDNF levels of the patients with panic disorder, and its correlation with therapeutic response to group cognitive behavioral therapy (CBT). Group CBT (10 consecutive 1 h weekly sessions) was administered to the patients with panic disorder after consulting the panic outpatient special service. Before treatment, serum concentrations of BDNF and total cholesterol were measured. After treatment, we defined response to therapy as a 40% reduction from baseline on Panic Disorder Severity Scale (PDSS) score as described by [Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]. There were 26 good responders and 16 poor responders. 31 age- and sex-matched healthy normal control subjects were also recruited in this study. The serum BDNF levels of the patients with poor response (25.9 ng/ml [S.D. 8.7]) were significantly lower than those of the patients with good response (33.7 ng/ml [S.D. 7.5]). However, there were no significant differences in both groups of the patients, compared to the normal controls (29.1 ng/ml [S.D. 7.1]). No significant differences of other variables including total cholesterol levels before treatment were detected between good responders and poor responders. These results suggested that BDNF might contribute to therapeutic response of panic disorder. A potential link between an increased risk of secondary depression and BDNF remains to be investigated in the future.

Authors+Show Affiliations

Department of Psychiatry (K2), Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15905010

Citation

Kobayashi, Keisuke, et al. "Serum Brain-derived Neurotrophic Factor (BDNF) Levels in Patients With Panic Disorder: as a Biological Predictor of Response to Group Cognitive Behavioral Therapy." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 29, no. 5, 2005, pp. 658-63.
Kobayashi K, Shimizu E, Hashimoto K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):658-63.
Kobayashi, K., Shimizu, E., Hashimoto, K., Mitsumori, M., Koike, K., Okamura, N., Koizumi, H., Ohgake, S., Matsuzawa, D., Zhang, L., Nakazato, M., & Iyo, M. (2005). Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Progress in Neuro-psychopharmacology & Biological Psychiatry, 29(5), 658-63.
Kobayashi K, et al. Serum Brain-derived Neurotrophic Factor (BDNF) Levels in Patients With Panic Disorder: as a Biological Predictor of Response to Group Cognitive Behavioral Therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):658-63. PubMed PMID: 15905010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. AU - Kobayashi,Keisuke, AU - Shimizu,Eiji, AU - Hashimoto,Kenji, AU - Mitsumori,Makoto, AU - Koike,Kaori, AU - Okamura,Naoe, AU - Koizumi,Hiroki, AU - Ohgake,Shintaro, AU - Matsuzawa,Daisuke, AU - Zhang,Lin, AU - Nakazato,Michiko, AU - Iyo,Masaomi, PY - 2005/04/06/accepted PY - 2005/5/21/pubmed PY - 2005/8/27/medline PY - 2005/5/21/entrez SP - 658 EP - 63 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog Neuropsychopharmacol Biol Psychiatry VL - 29 IS - 5 N2 - Little is known about biological predictors of treatment response in panic disorder. Our previous studies show that the brain-derived neurotrophic factor (BDNF) may play a role in the pathophysiology of major depressive disorders and eating disorders. Assuming that BDNF may be implicated in the putative common etiologies of depression and anxiety, the authors examined serum BDNF levels of the patients with panic disorder, and its correlation with therapeutic response to group cognitive behavioral therapy (CBT). Group CBT (10 consecutive 1 h weekly sessions) was administered to the patients with panic disorder after consulting the panic outpatient special service. Before treatment, serum concentrations of BDNF and total cholesterol were measured. After treatment, we defined response to therapy as a 40% reduction from baseline on Panic Disorder Severity Scale (PDSS) score as described by [Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]. There were 26 good responders and 16 poor responders. 31 age- and sex-matched healthy normal control subjects were also recruited in this study. The serum BDNF levels of the patients with poor response (25.9 ng/ml [S.D. 8.7]) were significantly lower than those of the patients with good response (33.7 ng/ml [S.D. 7.5]). However, there were no significant differences in both groups of the patients, compared to the normal controls (29.1 ng/ml [S.D. 7.1]). No significant differences of other variables including total cholesterol levels before treatment were detected between good responders and poor responders. These results suggested that BDNF might contribute to therapeutic response of panic disorder. A potential link between an increased risk of secondary depression and BDNF remains to be investigated in the future. SN - 0278-5846 UR - https://www.unboundmedicine.com/medline/citation/15905010/Serum_brain_derived_neurotrophic_factor__BDNF__levels_in_patients_with_panic_disorder:_as_a_biological_predictor_of_response_to_group_cognitive_behavioral_therapy_ DB - PRIME DP - Unbound Medicine ER -